Nutrient quality
The phospholipid-rich oil supports absorption, and the focused ingredient set avoids obvious padding. Modest EPA and DHA amounts limit the practical omega-3 contribution.
.| $ 16.78 | ||
| $ 22.37 | ||
Vitacost | $ 22.37 |
The softgel provides 500 mg of krill oil with 81 mg EPA and 52 mg DHA. Its 200 mg phospholipid content may support absorption, while astaxanthin offers basic oxidation protection.
The combined EPA and DHA amount is small. A single softgel is convenient, but users seeking meaningful omega-three intake would need a more concentrated product.
Purification and independent contaminant testing are not supplied. Cost per gram of active EPA and DHA is also weak despite the moderate serving price.
The phospholipid-rich oil supports absorption, and the focused ingredient set avoids obvious padding. Modest EPA and DHA amounts limit the practical omega-3 contribution.
.Individual omega-3 fatty acids, phospholipids, and astaxanthin have stated amounts. Serving guidance and inactive ingredients are not fully represented in the supplied label data.
.The aggregate rating is strong, but the review volume is only moderate. No review text is supplied to assess repeated complaints or purpose-specific experiences.
.The focused formula and low serving burden provide some practical value. Low EPA and DHA delivery weakens value for anyone seeking a meaningful active omega-3 amount.
.| Ingredient | Amount per serving |
|---|---|
Krill Oil | 500 mg |
Omega-3 Fatty Acids | 133 mg |
Eicosapentaenoic Acid | 81 mg |
Docosahexaenoic Acid | 52 mg |
Phospholipids | 200 mg |
Astaxanthin | 500 mcg |
Krill oil supplies DHA in a phospholipid form, which supports good bioavailability. The 52 mg DHA serving is below the collection's moderate-dose threshold. Oxidation protection is present, and Krill oil lacks explicit third-party purity verification.
Phospholipid-rich krill oil supports absorption; ePA density is low, and only one protective antioxidant is evident. The serving provides a minimal EPA amount with a clearly EPA-centric ratio. No purification or third-party verification is shown, while normalized cost is weak.